Johnson and Johnson Newswire

Comprehensive Real-Time News Feed for Johnson and Johnson.

Results 1 - 20 of 2,327 in Johnson and Johnson

  1. We were guinea pigs say victims, as hip replacement class action beginsRead the original story w/Photo

    24 min ago | The Age

    Recipients of a controversial metal-on-metal hip replacement implant say they were guinea pigs for a faulty device that has left thousands of people in constant pain and others with heavy metal poisoning. On the opening day of a Federal Court class action against the company that designed the metal hips, DePuy, and the product's distributor Johnson & Johnson, the victims of the devices demanded that those responsible be held to account.


  2. UPDATE 1-Amgen says Kyprolis doubles progression-free survival vs VelcadeRead the original story

    3 hrs ago | Reuters

    Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday. Kyprolis, the centerpiece of Amgen's nearly $10 billion acquisition of Onyx Pharmaceuticals in 2013, had sales last year of $331 million.


  3. Amgen says a study found its cancer drug more effected than rival drugRead the original story w/Photo

    4 hrs ago | Los Angeles Times

    Amgen Inc. said cancer patients treated with Kyprolis for relapse of multiple myeloma lived longer than those treated with a rival drug. Amgen Inc. said cancer patients treated with Kyprolis for relapse of multiple myeloma lived longer than those treated with a rival drug.


  4. Investors urged to look offshoreRead the original story w/Photo

    7 hrs ago | West Australian

    Veteran funds manager and stock picker John Abernethy has urged Australian investors to broaden their investment horizons beyond our sparsely-populated antipodean island. The investment chief of research and funds management group Clime has warned that our domestic equities market was over-represented by banks and resources stocks and had limited to key market trends and major sectors.


  5. After growing 46DD breasts, man wins $2.5 million from drug companyRead the original story w/Photo

    7 hrs ago |

    A 20-year-old Alabama man with autism was awarded $2.5 million in damages on Tuesday by a Philadelphia jury that found a drug he began taking as a child caused him to grow large breasts and that his family was not "adequately warned" of this side effect, according to a report by The Philadelphia Daily News. A Common Pleas jury found that Austin Pledger, his family and his doctor were not aware that the drug Risperdal -- an anti-psychotic made by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson -- could cause him to grow 46DD breasts, Pledger's attorney Thomas Kline told the Daily News.


  6. Doing This Could Derail Your RetirementRead the original story w/Photo

    17 hrs ago | The Motley Fool

    One of the biggest fears facing all of us is that our retirements won't be financially secure. As employers have throttled back on providing pensions, workers are increasingly on the hook for generating their own retirement income to complement Social Security.


  7. Just How Different Are These Healthcare ETFs?Read the original story w/Photo

    21 hrs ago | Seeking Alpha

    It is not a stunning revelation that the healthcare sector is again a star this year and by the looks of the broad-based strength across exchange traded funds tracking the sector, plenty of investors know this. On Wednesday, 195 ETFs made all-time highs, 25 of which were healthcare funds.


  8. Autistic Man Wins $2.5M In Damages After Antipsychotic Drug Gives Him 46DD BreastsRead the original story

    Saturday | Medical Daily

    A man taking an antipsychotic drug known as Risperdal developed gynecomastia, or the condition in which men grow female breasts. A 20-year-old Alabama man won a lawsuit against Janssen Pharmaceuticals after an antipsychotic drug caused him to develop size 46DD breasts.


  9. One Man's OpinionDID Middle East Meeting Bomb on Broadway?Read the original story

    Friday | American Reporter

    Nineteen-thirty-five was not that great a year for America. The country was still in the Depression.


  10. Court: Company must pay SC $136 million over drug marketingRead the original story w/Photo

    Friday | ABC News 4 Charleston

    South Carolina's high court says a Johnson & Johnson subsidiary should pay the state $136 million over deceptive drug marketing of an anti-psychotic drug. The ruling from the state Supreme Court reduced by more than half the original penalties levied against Janssen Pharmaceutica by a Spartanburg County jury.


  11. Hershey names CFO and MondelA"z picks North America headRead the original story w/Photo

    Friday Feb 27 | Confectionery News

    Hershey has appointed Patricia A. Little as its new chief financial officer, while MondelA'z has named Roberto Marques as president of its North America business. Little joins Hershey from temp staffing agency Kelly Services.


  12. Pharmaceutical Industry and Malpractice Topic Of Author VisitRead the original story w/Photo

    Friday Feb 27 | The Black River News

    Author Bill Powers ' debut title, The Pharm House shares a story involving the pharmaceutical industry and malpractice of epic proportions. In this suspenseful thriller, Powers investigates the underworld of the international pharmaceutical industry, which includes unscrupulous activities at the hands of corporate lieges traversing the planet and seducing young women while soliciting, marketing, manufacturing and selling legalized addiction under the guise of medicinal purpose! The scenes are seamy and torrid as well as realistic and matter of fact.


  13. People Are Buying Johnson & Johnson, But I'm Not Just YetRead the original story w/Photo

    Friday Feb 27 | Seeking Alpha

    The current trend for the share price of JNJ is down, and the trend is your friend, thus a better entry point may loom ahead. I have had previously been invested in Johnson & Johnson and have been looking for another entry point for about a month or so now, as I am beginning to rebuild by dividend growth portfolio.


  14. Johnson & Johnson's shared services search comes amid a cost-cutting moveRead the original story w/Photo

    Friday Feb 27 | Business Journal

    The search for a North American headquarters for a shared services operation by Johnson & Johnson Services comes amid a $1 billion cost-cutting initiative by its parent company, Johnson & Johnson Inc. .


  15. State Farm Profit Falls 19% as Car Underwriting Loss WidensRead the original story

    Friday Feb 27 | The Washington Post

    State Farm Mutual Automobile Insurance Co., the largest U.S. property-casualty insurer, said 2014 profit fell 19 percent as the underwriting loss widened on car coverage. Net income for the year fell to $4.2 billion from $5.2 billion in 2013, the Bloomington, Illinois-based company said Friday in a statement.


  16. $25 Million is What Google Inc (GOOGL) Paid for the .app Web DomainRead the original story w/Photo

    Friday Feb 27 | Insider Monkey

    Google Inc has won the bid for the .app domains in the auction held by Internet Corporation for Assigned Names and Numbers , the organization that controls the world's domain names, with $25,001,000 which is the highest one bid ever for any domain to date, BBC News reported today. There were 13 other companies that applied for the .app domain name such as


  17. South Carolina Court Orders J&J to Pay $136M in Risperdal CaseRead the original story w/Photo

    Friday Feb 27 | Insurance Journal West

    South Carolina's Supreme Court ordered Johnson & Johnson to pay a penalty of $136 million, upholding a jury's finding that the drugmaker's Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks. A trial court had earlier ordered J&J to pay $327 million, but the Supreme Court more than halved that penalty, citing a provision in South Carolina law that no action can be taken in such cases after three years of the discovery of unlawful conduct.


  18. Medical Device Market to Reach $361 BillionRead the original story w/Photo

    Friday Feb 27 | JD Supra

    According to an article in Medical Design Technology , Kalorama Information's 2014 report on The Global Market for Medical Devices estimated that the global market for medical devices was expected to reach $361 billion by year's end, reflecting somewhat slower than expected growth in the industry. Looking forward, the article projects that at an average growth rate of 3%, the global medical device market should grow to $427 billion in 2018.


  19. J&J Must Pay $2.5M to Young Man Who Grew 46 DD BreastsRead the original story w/Photo

    Friday Feb 27 | NBC Philadelphia

    A Philadelphia jury said Tuesday that drugmaker Johnson & Johnson should pay $2.5 million to a 20-year-old man with autism from Alabama - who developed size 46 DD breasts as a young teenager - because the company failed to adequately warn of that potential side effect from his use of the antipsychotic drug Risperdal. This was the first case related to the condition called gynecomastia that went to a jury, but thousands more lawsuits are lined up in Philadelphia, California, Missouri, and other locations.


  20. Why Emerson Electric Returns 7% Per Year For Long-Term Dividend Investors, Despite Low Oil PricesRead the original story w/Photo

    Friday Feb 27 | Seeking Alpha

    Given the current yield of 3.2% and the share buyback program, investors can expect an annual return around 7%. Emerson Electric is Missouri-based multinational corporation, manufacturing products and providing engineering services to consumer, industrial and commercial markets in over 200 manufacturing locations.